Our top pick for
Xylem Inc is a specialty industrial machinery business based in the US. Xylem shares (XYL) are listed on the NYSE and all prices are listed in US Dollars. Xylem employs 15,600 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$124.69|
|52-week range||$83.29 - $138.78|
|50-day moving average||$129.65|
|200-day moving average||$121.25|
|Wall St. target price||$120.64|
|Dividend yield||$1.08 (0.88%)|
|Earnings per share (TTM)||$2.12|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||2.65%|
|1 month (2021-09-17)||-5.22%|
|3 months (2021-07-17)||3.01%|
|6 months (2021-04-16)||14.81%|
|1 year (2020-10-16)||36.24%|
|2 years (2019-10-17)||58.22%|
|3 years (2018-10-17)||74.78%|
|5 years (2016-10-17)||153.43%|
Valuing Xylem stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xylem's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Xylem's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Xylem shares trade at around 59x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Xylem's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4069. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Xylem's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Xylem's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $875 million.
The EBITDA is a measure of a Xylem's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$5.2 billion|
|Operating margin TTM||12.04%|
|Gross profit TTM||$1.8 billion|
|Return on assets TTM||4.54%|
|Return on equity TTM||13.02%|
|Market capitalisation||$22.5 billion|
TTM: trailing 12 months
There are currently 4.1 million Xylem shares held short by investors – that's known as Xylem's "short interest". This figure is 15.5% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting Xylem shares can be evaluated.
Xylem's "short interest ratio" (SIR) is the quantity of Xylem shares currently shorted divided by the average quantity of Xylem shares traded daily (recently around 785410.79545455). Xylem's SIR currently stands at 5.28. In other words for every 100,000 Xylem shares traded daily on the market, roughly 5280 shares are currently held short.
However Xylem's short interest can also be evaluated against the total number of Xylem shares, or, against the total number of tradable Xylem shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xylem's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Xylem shares in existence, roughly 20 shares are currently held short) or 0.0231% of the tradable shares (for every 100,000 tradable Xylem shares, roughly 23 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Xylem.
Find out more about how you can short Xylem stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Xylem.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 17.42
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Xylem's overall score of 17.42 (as at 12/31/2018) is excellent – landing it in it in the 11st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Xylem is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.03/100
Xylem's environmental score of 4.03 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Xylem is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 5.78/100
Xylem's social score of 5.78 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Xylem is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 6.61/100
Xylem's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Xylem is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Xylem scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Xylem has, for the most part, managed to keep its nose clean.
|Total ESG score||17.42|
|Total ESG percentile||11.14|
|Environmental score percentile||2|
|Social score percentile||2|
|Governance score percentile||2|
|Level of controversy||2|
Dividend payout ratio: 41.51% of net profits
Recently Xylem has paid out, on average, around 41.51% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.9% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Xylem shareholders could enjoy a 0.9% return on their shares, in the form of dividend payments. In Xylem's case, that would currently equate to about $1.08 per share.
While Xylem's payout ratio might seem fairly standard, it's worth remembering that Xylem may be investing much of the rest of its net profits in future growth.
Xylem's most recent dividend payout was on 22 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 24 August 2021 (the "ex-dividend date").
Over the last 12 months, Xylem's shares have ranged in value from as little as $83.2888 up to $138.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Xylem's is 1.0619. This would suggest that Xylem's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Xylem Inc. , together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally. It operates in three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment under the Flygt, Godwin, Wedeco, Sanitaire, and Leopold names for the transportation and treatment of water. The Applied Water segment provides pumps, valves, heat exchangers, controls, and dispensing equipment systems under the Goulds Water Technology, Bell & Gossett, A-C Fire Pump, Standard Xchange, Lowara, Jabsco, and Flojet brand names for residential and commercial building services, and industrial water applications. The Measurement & Control Solutions segment provides smart metering, networked communications, and measurement and control technologies, as well as critical infrastructure technologies that allow customers to use their distribution networks for the delivery, monitoring, and control of critical resources, such as water, electricity, and natural gas. It also offers software and services, including cloud-based analytics, remote monitoring, data management and analytics, leak detection, condition assessment, asset management, and pressure monitoring solutions, as well as testing equipment and managed services.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.